Neurocrine Biosciences has rallied back to resistance, but one
investor is worried about a pullback.
optionMONSTER's Depth Charge monitoring program detected the
purchase of 2,000 August 9 puts for $1.05 and the sale of an equal
number of August 15 calls for $0.90. Volume was more than triple
open interest at each strike, showing that this is new positioning.
The trader probably owns shares in the drug developer and is using
the options as a hedge. The investor paid $0.15 to implement this
position and has now locked in a minimum selling price of $9 and a
maximum selling price of $15. Those levels would be $8.85 and
$14.85, respectively, including the cost.
NBIX fell 1.42 percent to $11.78 yesterday but is up 57 percent so
far this year. It's been sitting around the same price area where
it peaked in late 2007, shortly before it gapped violently lower.
That could be leading some chart watchers to expect sellers to step
Total option volume was 10 times greater than average in the
session, according to the Depth Charge.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.
Copyright © 2010 OptionMonster® Holdings, Inc. All Rights Reserved.